Facing COVID-19 in the Hematopoietic Cell Transplant Setting: A New Challenge for Transplantation Physicians
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
UMass Chan Affiliations
Department of Medicine, Division of Hematology and OncologyDocument Type
Letter to the EditorPublication Date
2020-04-11Keywords
COVID-19cancer
hematopoietic cell transplantation
HCT
blood donation
Health Services Administration
Hematology
Hemic and Lymphatic Diseases
Infectious Disease
Neoplasms
Oncology
Virus Diseases
Metadata
Show full item recordAbstract
Coronavirus disease (COVID-19) Pandemic has put enormous pressure on the health care system worldwide. As of 8th April 2020, more than 220 countries are already affected with a total of 1,462,698 confirmed COVID-19 cases and 84,792 deaths across the globe [1]. Absence of a specific antiviral agent and vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has strangled the treating health care providers. The special population that is at high risk of acquiring SARS-CoV 2 infection are immunocompromised, and HIV infected persons, pregnant woman, and cancer patients [2]. We hereby discuss the challenges being faced by cancer patients, specifically the transplant recipients and their respective donors during COVID-19 pandemic. Transplantation societies are working closely to provide optimal support and recommendations to the transplant specialists to guide them to conduct hematopoietic cell transplantation (HCT) in the safest manner.Source
Sahu KK, Jindal V, Siddiqui AD, Cerny J. Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians. Blood Cells Mol Dis. 2020 Apr 11;83:102439. doi: 10.1016/j.bcmd.2020.102439. Epub ahead of print. PMID: 32353701; PMCID: PMC7151275. Link to article on publisher's site
DOI
10.1016/j.bcmd.2020.102439Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27422PubMed ID
32353701Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.bcmd.2020.102439